Clinical and laboratory diagnosis of invasive candida infection in neutropenic patients.
Cancer patients, especially those with acute leukaemia, represent a group that has the greatest risk for deep fungal infection. Almost no cases were seen before the advent of modern chemotherapy, and prior to the availability of antibacterial agents, less than 5% of patients with acute leukaemia died of fungal infection. These infections are now responsible for 40% or more of the deaths at some institutions. Candida species continues to be the most common fungal pathogen. Rapid and specific diagnosis of invasive candiosis enabling early effective therapy is therefore an important measure for reducing mortality in patients. Here the current status of clinical and laboratory diagnosis of invasive candida infection in neutropenic patients is discussed and recommendations made as to future development programmes.
Kalin
M
M
Department of Medicine, Karolinska Institute and Hospital, Stockholm, Sweden.
Petrini
B
B
D000970:Antineoplastic Agents / Q000009:adverse effects; D002177:Candidiasis / Q000175:diagnosis* / Q000276:immunology; D004198:Disease Susceptibility; D006801:Humans; D016867:Immunocompromised Host; D009369:Neoplasms / Q000150:complications*; D009503:Neutropenia / Q000150:complications*; D012307:Risk Factors
D000970:Antineoplastic Agents